MedTrace Logo

Omalizumab in Severe and Refractory Solar Urticaria

NCT02262130 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-10-12

Study results available
· View outcomes & findings →

Summary

Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on quality of life. New treatment options are warranted. The investigators aim to test the efficacy and the safety of omalizumab, an anti-IgE antibody recently approved in chronic spontaneous urticaria, in this setting.

Conditions

  • Solar Urticaria

Interventions

DRUG

Omalizumab

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Manuelle Viguier, MD, PhD · Assistance Publique-Hôpitaux de Paris, Université Paris 7

  • François AUBIN, Prof. · Centre hospitalier régional universitaire de Besançon

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-29
Completion
2015-09-29

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262130 on ClinicalTrials.gov